EditFrom NeuroLex
Alemtuzumab
| Name: | Alemtuzumab |
| Description: | Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Pharmacology: Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations. Mechanism of action: Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells. Drug type: Approved. Biotech. Investigational. Drug category: Antineoplastic Agents |
| Synonym(s): | alemtuzumab, Campath, Campath (ILEX Pharmaceuticals LP), MabCampath |
| Related to: | CAMPATH-1 antigen, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
| Has role: | Drug |
| Super-category: | Molecule |
| URL: | http://www.drugbank.ca/drugs/DB00087 |
| Id: | DB00087 |
| Link to OWL / RDF: | Download this content as OWL/RDF |
Facts about AlemtuzumabRDF feed
| Comment | taken from DrugBank |
| Curator | Ab + |
| DefiningCitation | http://www.drugbank.ca/drugs/DB00087 + |
| Definition | Humanized monoclonal antibody specific to … Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Pharmacology: Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations. Mechanism of action: Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells. Drug type: Approved. Biotech. Investigational. Drug category: Antineoplastic Agents onal. Drug category: Antineoplastic Agents |
| Has role | Drug + |
| Id | DB00087 + |
| Label | Alemtuzumab + |
| ModifiedDate | 5 February 2010 + |
| RelatedTo | CAMPATH-1 antigen +, High affinity immunoglobulin gamma Fc receptor I +, Low affinity immunoglobulin gamma Fc region receptor III-B +, Complement C1r subcomponent +, Complement C1q subcomponent subunit A +, Complement C1q subcomponent subunit B +, Complement C1q subcomponent subunit C +, Low affinity immunoglobulin gamma Fc region receptor III-A +, Low affinity immunoglobulin gamma Fc region receptor II-a +, Low affinity immunoglobulin gamma Fc region receptor II-b +, and Low affinity immunoglobulin gamma Fc region receptor II-c + |
| SuperCategory | Molecule + |
| Synonym | alemtuzumab +, Campath +, Campath (ILEX Pharmaceuticals LP) +, and MabCampath + |